About Prima Innovations LLC
Redefining Muscle Spasm Treatment Through Science and Clinical Insight
Prima Innovations LLC is a pre-clinical stage pharmaceutical company dedicated to developing a first-in-class topical muscle relaxant with antispasmodic action designed to act directly within skeletal muscle tissue.
Headquartered in Wayne, New Jersey, Prima Innovations was founded on a powerful convergence of clinical experience and pharmaceutical innovation. While muscle spasms originate in skeletal muscle, most available medications for painful muscle spasms act centrally through the nervous system. Prima Innovations is advancing a localized skeletal muscle relaxant designed to address muscle hyperactivity at its source.
Our patented muscle relaxant drug platform reflects years of interdisciplinary collaboration between occupational therapy innovation, pharmacologic science, and pharmaceutical development expertise.
Our Mission
Our mission is to improve the lives of millions of individuals who suffer from debilitating muscle spasms, acute musculoskeletal pain, and chronic muscle hyperactivity by advancing targeted, science-driven pharmaceutical innovation.
We are committed to:
Developing a topical skeletal muscle relaxant with defined antispasmodic effect
Advancing regulatory-aligned clinical development
Expanding treatment possibilities for back pain muscle relaxant and neck pain muscle spasm relief
Reducing reliance on systemic CNS-targeted therapies
Prima Innovations is building a differentiated therapeutic pathway within muscle spasm treatment.
Leadership
Our Leadership Team
Decades of combined expertise across clinical care, drug development, and strategic pharma commercialization.
Mandar Shah, Ph.D.
COO & Co-Founder
Dr. Mandar Shah is an innovative pharmaceutical professional with deep expertise in developing new chemical entities (NCEs), generic products, prescription (Rx), over-the-counter (OTC), and surgical formulations across both large and small pharmaceutical companies in the United States and India. He is the inventor of more than 110 patents and has contributed to the development of multiple new drugs and innovative dosage forms.
Dr. Shah’s expertise includes:
- Complex topical and transdermal formulation systems
- Difficult-to-formulate and difficult-to-manufacture products
- Strategic patent positioning and “evergreening” of drug assets
- Development of non-infringing pharmaceutical products
- Regulatory strategy integration
- Business development and client interface management
He is recognized for creating innovative business, regulatory, and legal strategies that fuse product conceptualization with development and optimized product positioning.
At Prima Innovations, Dr. Shah leads:

- Pharmaceutical formulation refinement
- Regulatory planning
- Intellectual property strategy
- Manufacturing pathway design
- Investor engagement
His combination of scientific innovation and strategic commercialization insight positions Prima Innovations for disciplined clinical advancement and long-term value creation.
Priti Shah, OTR, CHT
CEO & Co-Founder | Clinical Innovator
Priti Shah is a highly innovative Occupational Therapist and Certified Hand Therapist whose decades of clinical experience directly inspired the development of Prima Innovations’ topical antispasmodic drug platform.
Since 1988, Priti has worked across Georgia, Texas, and New Jersey, treating complex musculoskeletal and neurological conditions that affect functional independence. In 2010, she founded Allies in Hand Therapy, a successful and expanding therapy practice in Northern New Jersey.
Recognized within the local medical community as a trusted specialist for complicated cases, Priti has built her career on thinking beyond conventional protocols. Her expertise spans:

- Complex upper extremity rehabilitation
- Lymphedema management
- Dry needling techniques
- Kinesio taping
- Advanced splinting and orthotic design
Over the years, she has developed custom splints and orthotic devices to improve biomechanical alignment and hand function.
Through firsthand experience treating patients suffering from severe muscle spasms, she identified a critical gap in available therapies — the lack of a topical antispasmodic medication that reduces debilitating spasms without limiting a patient’s ability to function during normal daily activities.
Her clinical insight became the foundation for Prima Innovations’ localized muscle relaxant strategy.
Thomas Argentieri, Ph.D.
Scientific & Strategic Advisor
Dr. Thomas Argentieri is a seasoned pharmaceutical and biotech executive with over 30 years of experience spanning academic research, industrial R&D, and business development.
He earned his Ph.D. in Pharmacology from Rutgers University, specializing in ion channel biophysics — a critical scientific domain relevant to muscle contraction and spasm physiology. He completed postdoctoral training at the University of Pennsylvania and later served as Assistant Professor in UPenn’s Department of Medicine, where he studied mechanisms of cardiac arrhythmias.
Following his academic career, Dr. Argentieri transitioned into industry leadership roles, including:
- Section Head at Berlex Pharmaceuticals, where he helped build antiarrhythmic and antihypertensive drug discovery programs and advanced two drugs into clinical development
- Director of Wyeth Pharmaceuticals’ Urologic Disorders division, overseeing development of therapies for overactive bladder
He has authored more than 70 peer-reviewed manuscripts, review articles, and book chapters and holds 10 patents.
In 2004, Dr. Argentieri transitioned into business development, leading in-licensing and out-licensing activities and executing numerous transactions across pharmaceutical and biotech sectors.
He is the Founder of BioSense Solutions, providing scientific evaluation, licensing, and business development expertise to life sciences companies. He also serves on the editorial board of the Journal of Pharmacology and Experimental Therapeutics.

His combined expertise in ion channel pharmacology, clinical drug development, and business strategy strengthens Prima Innovations’ scientific credibility and commercial positioning.
Growth and Team Expansion
Prima Innovations is entering a pivotal stage as we prepare for formal clinical evaluation of our topical muscle relaxant with antispasmodic action.
To support this next phase, we are actively seeking to add at least one experienced professional to our team. Ideal candidates may have backgrounds in:
- Clinical development and trial operations
- Regulatory affairs and FDA submissions
- CMC and pharmaceutical manufacturing strategy
- Biostatistics or translational pharmacology
- Early-stage biotech business development
This is an opportunity to join a scientifically rigorous, innovation-driven pre-clinical stage pharmaceutical company advancing a differentiated muscle relaxant drug platform with strong intellectual property protection.
Interested professionals are encouraged to contact:
Mandar Shah, Ph.D.
COO & Co-Founder
Mshah@primainnovationsllc.com
Commitment to Responsible Innovation
Prima Innovations operates with a strong commitment to scientific integrity, regulatory compliance, and responsible clinical advancement. Our investigational topical skeletal muscle relaxant has not yet received regulatory approval. All development will proceed through structured clinical trials and regulatory review.
We believe that combining clinical insight, pharmaceutical innovation, and disciplined execution will create a meaningful advancement in muscle spasm treatment.
Building the Future of Targeted Muscle Relaxant Therapy
Prima Innovations LLC is advancing a patented topical muscle relaxant platform designed to address muscle spasms at their origin. Through interdisciplinary leadership and strategic growth, we are building a next-generation approach to antispasmodic medication development.

We welcome engagement from investors, collaborators, and experienced professionals interested in shaping the future of localized muscle relaxant therapy.
Investor & Partnership Inquiries
We invite investors and strategic partners to connect with us to learn more about our topical muscle relaxant platform and clinical development strategy.
Thank you for contacting us.We’ll get back to you as soon as possible.
We got it.
Ready to begin?
You don’t have to take the next step alone.
Reaching out is the first step.
